Accelerate Diagnostics, Inc (AXDX): Net earnings per share (EPS TTM)

Accelerate Diagnostics (AXDX) leads in rapid sepsis diagnostics, reducing therapy selection time to a few hours. The rolling annual EPS trend visualizes profit dynamics, where -2.13 is the current value of the metric. Revenues rely on the sale of reagents and equipment, while the growth strategy is based on partnering with a global distributor to reduce the rate of capital expenditure.

AXDX Accelerate Diagnostics Inc Net earnings per share for the last four quarters (07/04/2022 - 05/24/2025)

AXDX (Accelerate Diagnostics Inc.): analytical breakdowns and indicator data

- current quotes and average value forecast:

Price Chart Accelerate Diagnostics|AXDX - Analyst Median Target

- stock exchange capitalization data:

Market Capitalization Accelerate Diagnostics, Inc.|AXDX - Company Buyout Price

- business book valuation details:

Net Assets per Single Share Accelerate Diagnostics|AXDX - Book Valuation of Business|Market Capitalization to Book Value Ratio acceleratediagnostics.com|AXDX - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

AXDX - Company Net Income|Expected Profit Accelerate Diagnostics|AXDX - Company Value to Net Income|Forward P/E Multiple Accelerate Diagnostics, Inc.|AXDX - PEG Multiple|Enterprise Value to EBITDA Ratio Accelerate Diagnostics, Inc.|AXDX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Accelerate Diagnostics|AXDX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months acceleratediagnostics.com|AXDX - Earnings per share increase in current year|Earnings growth forecast for next year Accelerate Diagnostics

Initial company analysis:Accelerate Diagnostics (AXDX)

Manufactured products of Accelerate Diagnostics Inc.

Accelerate Diagnostics (AXDX) minimizes medical risks by providing rapid infection identification systems to optimize antibiotic therapy. Annual net income per share reflects the actual return on a single security, excluding the impact of issuances. By analyzing the TTM earnings per share trend, an investor sees a cash flow stripped of structural noise. This indicator confirms the stability of revenues from reagent sales. Ignoring a downward trend in this metric risks freezing investment capital.

Main competitors